title: [Clinical studies of faropenem in the field of obstetrics and gynecology].
abstract: The clinical effect of faropenem was evaluated in 165 ambulatory patients with various infections in the field of obstetrics and gynecology at 10 institutions in Yamagata Prefecture. The results obtained are summarized below. 1. The rate of efficacy, as determined from the clinical effect following 3- to 7-day repeated administration at a dose of 600 mg/day, was 97.9% (46/47) for intrauterine infections, 92.0% (23/25) for adnexitis, 93.8% (15/16) for external genital infections, 88.9% (8/9) for mastitis, 94.0% (63/67) for cystitis, and 100% (1/1) for cervicitis. The overall efficacy rate was estimated to be 94.5% (156/165). 2. The rate of clinical efficacy, as classified by isolate, was high, 95.1% for Gram-positive bacteria, 100% for Gram-negative bacteria, and 100% for anaerobes. As for bacteriological response classified by isolate, the eradication rate was high, 91.4% (74/81) for Gram-positive bacteria, 98.4% (62/63) for Gram-negative bacteria, 89.5% (17/19) for anaerobes, and 93.9% (153/163) in all. 3. No adverse reactions or laboratory abnormalities were observed in any patient. The results presented suggest that faropenem is a highly safe and effective antibiotic for the treatment of obstetric or gynecological infections of various kinds in an ambulatory setting.
authors.affiliation: Department of Obstetrics and Gynecology, Shirataka Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Chimura
authors.forename: N
authors.initials: N
authors.lastname: Kaneko
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: T
authors.initials: T
authors.lastname: Funayama
authors.forename: M
authors.initials: M
authors.lastname: Numazaki
authors.forename: T
authors.initials: T
authors.lastname: Oda
authors.forename: K
authors.initials: K
authors.lastname: Murayama
authors.forename: N
authors.initials: N
authors.lastname: Morisaki
authors.forename: T
authors.initials: T
authors.lastname: Hirayama
authors.forename: F
authors.initials: F
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Akatsuka
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D003556:Cystitis / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006801:Humans; D007769:Lactams; D008413:Mastitis / Q000188:drug therapy; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D002575:Uterine Cervicitis / Q000188:drug therapy; D014591:Uterine Diseases / Q000188:drug therapy; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D007769:Lactams; D047090:beta-Lactams; C107057:fropenem